Literature DB >> 15036167

The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson's disease.

Nicolas Simon1, Radka Gantcheva, Bernard Bruguerolle, François Viallet.   

Abstract

LevoDOPA given orally may compete with the neutral aminoacids contained in food for its absorption in the small intestine. LevoDOPA plasma kinetics of the morning intake with 'french' breakfast (low protein content) were compared with those of the noon intake with lunch (normal protein content) in 20 advanced parkinsonian patients (mean disease duration: 10 years). The galenic form and the dosage of levoDOPA were strictly the same for morning and noon intakes in each patient. Blood samplings were collected at T0 (just before intake) and successively at 15, 30, 45, 60, 90, 120, 150 and 180 min after intake. LevoDOPA plasma levels were further measured with HPLC method, then giving the following variables: Cmax (peak concentration), Tmax (time corresponding to Cmax), AUC (area under curve). The results showed no significant difference for Cmax and Tmax whereas the AUC was significantly (P < 0.001) increased for the noon intake, due to the trough concentration effect. These data suggest that, since rich protein diet has been shown to impair the clinical effect of LevoDOPA, this protein effect is probably not due to competitive intestinal absorption of LevoDOPA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036167     DOI: 10.1016/j.parkreldis.2003.10.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

Review 1.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

2.  Modulation of nutritional state in Parkinsonian patients with bilateral subthalamic nucleus stimulation.

Authors:  Joana Guimarães; Eduarda Matos; Maria José Rosas; Augusta Vieira-Coelho; Nuno Borges; Flora Correia; Rui Vaz; Carolina Garrett
Journal:  J Neurol       Date:  2009-12       Impact factor: 4.849

3.  Levodopa availability improves with progression of Parkinson's disease.

Authors:  Dirk Woitalla; Oliver Goetze; Jeong I Kim; Alice B Nikodem; Wolfgang E Schmidt; Horst Przuntek; Thomas Müller
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

4.  Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems.

Authors:  Yeon Hong Lee; Kyung Hee Kim; In Kyung Yoon; Kyung Eun Lee; In Koo Chun; Jeong Yeon Rhie; Hye Sun Gwak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-12-21       Impact factor: 2.441

5.  Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations.

Authors:  Michela Barichella; Chiara Savardi; Andrea Mauri; Agnieszka Marczewska; Antonella Vairo; Cinzia Baldo; Arianna Massarotto; Sara Elisabetta Cordara; Gianni Pezzoli
Journal:  Nutr Neurosci       Date:  2007 Jun-Aug       Impact factor: 4.994

6.  Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.

Authors:  Tuhin Virmani; Sirinan Tazan; Pietro Mazzoni; Blair Ford; Paul E Greene
Journal:  J Clin Mov Disord       Date:  2016-05-26

Review 7.  Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.

Authors:  Luxi Wang; Nian Xiong; Jinsha Huang; Shiyi Guo; Ling Liu; Chao Han; Guoxin Zhang; Haiyang Jiang; Kai Ma; Yun Xia; Xiaoyun Xu; Jie Li; Jing Y Liu; Tao Wang
Journal:  Front Aging Neurosci       Date:  2017-06-28       Impact factor: 5.750

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

9.  Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review.

Authors:  Jikke T Boelens Keun; Ilse Ac Arnoldussen; Chris Vriend; Ondine van de Rest
Journal:  Adv Nutr       Date:  2021-12-01       Impact factor: 8.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.